To include your compound in the COVID-19 Resource Center, submit it here.

Blinatumomab: Interim Phase II data

Interim data from a Phase II trial in 12 evaluable patients showed that 75% of patients achieved

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE